Exenatide (exendin-4) studies: 530 papers with results
Page 7 of 11
- The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.
Paul SK · Cardiovascular diabetology · 2015
Observational study · 12 results
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
Pendergrass M · Diabetes, obesity & metabolism · 2012
Observational study · 1 result
- Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Montilla S · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2014
Observational study · 11 results
- Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.
Matsuo K · Internal medicine (Tokyo, Japan) · 2013
Case report or series · 1 result
- Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.
Yammine L · Journal of addiction medicine · 2023
Case report or series · 4 results
- Exenatide-induced acute pancreatitis.
Ayoub WA · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2010
Case report or series · 7 results
- Improvement of psoriasis during exenatide treatment in a patient with diabetes.
Buysschaert M · Diabetes & metabolism · 2012
Case report or series · 7 results
- Exenatide and acute pancreatitis.
Tripathy NR · The Journal of the Association of Physicians of India · 2008
Case report or series · 3 results
- Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.
Shan SJ · The American Journal of dermatopathology · 2014
Case report or series · 1 result
- Acute tubulointerstitial nephritis following treatment with exenatide.
Nandakoban H · Diabetic medicine : a journal of the British Diabetic Association · 2013
Case report or series · 4 results
- Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Neves JS · European journal of heart failure · 2025
Other design · 10 results
- Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
Mentz RJ · Journal of the American Heart Association · 2018
Other design · 2 results
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
Bethel MA · Diabetes care · 2020
Other design · 12 results
- Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.
Macconell L · Diabetes, metabolic syndrome and obesity : targets and therapy · 2012
Other design · 10 results
- Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
Pencek R · Postgraduate medicine · 2012
Other design · 11 results
- Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS · Diabetes, obesity & metabolism · 2012
Other design · 15 results
- Population pharmacokinetics of exenatide.
Cirincione B · British journal of clinical pharmacology · 2017
Other design · 7 results
- Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
van der Aart-van der Beek AB · Diabetes, obesity & metabolism · 2020
Other design · 6 results
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Idzerda NMA · Diabetes, obesity & metabolism · 2020
Other design · 9 results
- Mechanism of the beneficial and protective effects of exenatide in diabetic rats.
Lotfy M · The Journal of endocrinology · 2014
Animal study (in vivo) · rat · 17 results
- Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.
Riederer A · Journal of veterinary internal medicine · 2016
Animal study (in vivo) · cat · 5 results
- Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas.
Fiorentino TV · JCI insight · 2019
Animal study (in vivo) · papio hamadryas · 10 results
- Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
Tao X · Journal of ovarian research · 2019
Animal study (in vivo) · rat · 6 results
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.
Nachnani JS · Diabetologia · 2010
Animal study (in vivo) · rat · 7 results
- The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.
Gilor C · Domestic animal endocrinology · 2011
Animal study (in vivo) · cat · 9 results
- The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.
Scott KA · American journal of physiology. Regulatory, integrative and comparative physiology · 2007
Animal study (in vivo) · rhesus macaque · 13 results
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu G · Diabetes · 1999
Animal study (in vivo) · rat · 5 results
- Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Arakawa M · Diabetes · 2010
Animal study (in vivo) · mouse · 10 results
- Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Timmers L · Journal of the American College of Cardiology · 2009
Animal study (in vivo) · pig · 12 results
- The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.
Dickson SL · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
Animal study (in vivo) · rat · 6 results
- Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
Kanoski SE · Endocrinology · 2011
Animal study (in vivo) · rat · 6 results
- Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA · Diabetes · 1999
Animal study (in vivo) · mouse, rat and rhesus monkey · 7 results
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Bertilsson G · Journal of neuroscience research · 2008
Animal study (in vivo) · rat and rodent · 7 results
- Entry of exendin-4 into brain is rapid but may be limited at high doses.
Kastin AJ · International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2003
Animal study (in vivo) · mouse · 8 results
- Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C · Diabetes · 2001
Animal study (in vivo) · rat · 12 results
- The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
Kanoski SE · Neuropharmacology · 2012
Animal study (in vivo) · rodents · 15 results
- Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.
Talsania T · Endocrinology · 2005
Animal study (in vivo) · mouse · 8 results
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S · The Journal of endocrinology · 2009
Animal study (in vivo) · mouse · 6 results
- Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.
Szayna M · Endocrinology · 2000
Animal study (in vivo) · rat · 8 results
- Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C · Diabetes · 2002
Animal study (in vivo) · rat · 9 results
- Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.
Stoffers DA · Diabetes · 2003
Animal study (in vivo) · rat · 4 results
- The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.
Egecioglu E · Psychoneuroendocrinology · 2013
Animal study (in vivo) · mouse and rat · 6 results
- Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
Park CW · Journal of the American Society of Nephrology : JASN · 2007
Animal study (in vivo) · mouse · 17 results
- Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.
Gedulin BR · Endocrinology · 2005
Animal study (in vivo) · rat · 15 results
- Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward.
Shirazi RH · PloS one · 2013
Animal study (in vivo) · rat · 2 results
- Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.
Teramoto S · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2011
Animal study (in vivo) · mouse · 6 results
- Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function.
Park S · The Journal of biological chemistry · 2006
Animal study (in vivo) · mouse · 11 results
- Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.
Ma X · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013
Animal study (in vivo) · rat · 17 results
- Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH · Diabetologia · 1999
Animal study (in vivo) · mouse and rat · 6 results
- Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.
Martin B · Diabetes · 2009
Animal study (in vivo) · mouse · 7 results